Rennes

• A study to test the safety, dosage and effectiveness of maribavir for the treatment of cytomegalovirus (CMV) infection in children and adole … Ended recruitment
  2023-508988-73-00 5 2025-10-29 Cytomegalovirus (CMV) infection in children and adolescents who have r
• A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection Ended recruitment
  2024-520062-54-00 4 2025-07-23 Chronic Hepatitis D Virus (HDV) Infection
• A Phase 2 Multicenter Study to Test the Effects of ALXN2220 on Markers of Disease Severity and the Safety of Re-Treatment in Patients with T … Ended recruitment
  2025-520506-35-00 4 2025-06-30 Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
• A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with SCLC Ended recruitment
  2024-516051-40-00 4 2025-06-10 Small Cell Lung Cancer (SCLC)
• A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection Ended recruitment
  2024-515919-22-00 5 2025-06-02 Chronic Hepatitis D Virus (HDV) Infection
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended recruitment
  2024-512925-95-00 5 2025-05-16 Advanced/Metastatic Breast Cancer
• ElderLIDO_1 : Pharmacokinetic study of intravenous lidocaine in young and elderly patients Ended recruitment
  2024-513932-11-00 6 2025-04-28 Anesthesia
• A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Ended recruitment
  2024-518343-38-00 5 2025-02-12 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
• A study to test an oral medicine, belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagn … Ended recruitment
  2023-505394-32-00 5 2025-02-06 chronic graft versus host disease
• A clinical trial to learn about the effects of YTB323 in people with difficult-to-treat severe inflammatory myopathies (IIM) Ended recruitment
  2024-514137-38-00 4 2025-02-04 Severe refractory idiopathic inflammatory myopathies (IIM)
• ANRS0407s -LKV.Cov40. A phase 1/2 multicenter, randomized study of the safety and immunogenicity of a sub-unit protein CD40.RBDv bivalent CO … Ended recruitment
  2023-504594-20-00 1 2025-01-06 Healthy volunteers
• A randomized, double-blind, parallel group, placebo-controlled multicenter study to evaluate efficacy, safety and tolerability of ianalumab … Ended recruitment
  2024-511933-36-00 4 2025-01-02 Diffuse cutaneous systemic sclerosis (dcSSc)
• Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended recruitment
  2023-504359-29-01 5 2024-12-11 Multiple sclerosis
• ICC APL STUDY 02 Treatment study for children and adolescents with Acute Promyelocytic Leukemia Ended recruitment
  2024-518669-83-00 4 2024-12-05 acute promyelocytic leukemia (APL) in children and adolescents
• DAPAgliflozine to attenuate cardiac RemOdeling afTEr aCuTe myOcardial infarction Ended recruitment
  2024-511882-13-01 5 2024-11-19 Cardiac failure
• ALS phase II study of NX210c (SEALS) Ended recruitment
  2023-508895-13-00 4 2024-10-25 Amyotrophic Lateral Sclerosis (ALS)
• A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended recruitment
  2023-504753-12-00 5 2024-10-01 Lung Cancer, Non-Small Cell
• A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended recruitment
  2023-509190-23-00 5 2024-09-03 Atherosclerotic Cardiovascular Disease Elevated lp(a)
• Comparison of an inhaled sedation strategy with an intravenous sedation strategy in intensive care patients treated with invasive mechanical … Ended recruitment
  2024-513530-37-00 5 2024-08-09 Delirium
• An intensive program with quadruplet induction and consolidation plus tandem autologous stem cell transplantation in Newly Diagnosed High Ri … Ended recruitment
  2023-509383-15-00 4 2024-07-05 Multiple Myeloma
• A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei … Ended recruitment
  2023-508306-15-00 5 2024-06-26 Alzheimer’s Disease
• Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone … Ended recruitment
  2023-508310-41-00 4 2024-06-26 Multiple myeloma
• A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab … Ended recruitment
  2022-502954-15-00 4 2024-06-21 Idiopathic pulmonary fibrosis
• A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants with Severe Alopecia Areata Ended recruitment
  2023-505061-82-01 5 2024-06-17 Alopecia Areata

Showing 289–312 of 519 trials